A pharmaceutical giant celebrated after its COVID-19 vaccine worked on young minors on Sept. 20.
Pfizer-BioNTech claims its low-dose immunization produced positive results among recipients aged between 5 and 11. The clinical trial involved reducing elementary school-aged recipient dosage by two-thirds of the recommended amount for adults.
“We are pleased to be able to submit data to regulatory authorities for this group of school-aged children before the start of the winter season,” BioNTech founding CEO Ugur Sahin said in a statement.
Pfizer revealed the one-third dosage was enough for children to achieve the same antibody levels as teenagers or young adults, who had the full dose, within a month of receiving the second jab.
The lower dose was tested on 2,268 subjects who were between 5 and 11 years-old.
Pfizer senior vice president Bill Gruber found a smaller dose resulted in fewer sore arms, fevers, and aches compared to adolescents who had the full dose according to the Associated Press.
Severe side effects seen in older recipients like myocarditis and blood clots were not mentioned. A low percentage of adverse reaction-linked fatalities have been reported worldwide, including the United States.
Inflammation of the heart muscle, also known as myocarditis, is understood to be more common among young adults–especially males. However, federal health agencies insist the condition happens rarely.
Pfizer Chairman and CEO Albert Bourla expects to seek U.S. Food and Drug Administration (FDA) authorization with “urgency.”
Pfizer is the only approved vaccine supplier to 12 year-olds across America.
Although children are less likely than adults to become severely ill from COVID-19, they can still transmit it to more vulnerable people. The Delta variant has already killed multiple young patients.
A lack of research on potential long-term effects the shots could have on military personnel has been widely criticized. Experts also realized vaccine protection could eventually wear off back in mid 2021.
The FDA and the Centers for Disease Control and Prevention insist the jab can prevent severe symptoms and reduce the chance of death.